Vikram Purohit
Stock Analyst at Morgan Stanley
(0.71)
# 3,895
Out of 4,947 analysts
154
Total ratings
25.86%
Success rate
-15.44%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Vikram Purohit
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HALO Halozyme Therapeutics | Upgrades: Overweight | $62 → $75 | $67.34 | +11.38% | 8 | Aug 6, 2025 | |
| ABSI Absci | Maintains: Overweight | $7 → $6.4 | $2.95 | +116.95% | 2 | Jul 28, 2025 | |
| RXRX Recursion Pharmaceuticals | Assumes: Equal-Weight | $5 | $5.83 | -14.16% | 4 | Jul 3, 2025 | |
| ASND Ascendis Pharma | Upgrades: Overweight | $180 → $250 | $197.07 | +26.86% | 19 | May 5, 2025 | |
| INCY Incyte | Maintains: Equal-Weight | $69 → $65 | $86.93 | -25.23% | 24 | Mar 24, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $125 → $190 | $109.42 | +73.65% | 19 | Feb 27, 2025 | |
| ZBIO Zenas BioPharma | Maintains: Overweight | $40 → $35 | $16.85 | +107.72% | 2 | Dec 11, 2024 | |
| FHTX Foghorn Therapeutics | Maintains: Equal-Weight | $6 → $9 | $5.05 | +78.22% | 9 | Sep 24, 2024 | |
| GMAB Genmab | Maintains: Equal-Weight | $31 | $23.26 | +33.28% | 2 | Sep 11, 2024 | |
| ABVX ABIVAX Société Anonyme | Maintains: Equal-Weight | $15 → $16 | $70.37 | -77.26% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $4.34 | +591.24% | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $10 | $16.73 | -40.23% | 8 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $46 → $6 | $2.90 | +107.25% | 1 | Nov 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $43 → $42 | $8.84 | +375.11% | 8 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $38 → $41 | $42.37 | -3.23% | 12 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $120 → $40 | $28.06 | +42.55% | 7 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $13 | $2.42 | +437.19% | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $39 → $38 | $19.53 | +94.57% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $24 → $20 | $11.05 | +81.00% | 5 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $13.23 | -24.41% | 11 | Jul 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $1.83 | +1,105.48% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $40 → $20 | $9.82 | +103.67% | 2 | Aug 5, 2020 |
Halozyme Therapeutics
Aug 6, 2025
Upgrades: Overweight
Price Target: $62 → $75
Current: $67.34
Upside: +11.38%
Absci
Jul 28, 2025
Maintains: Overweight
Price Target: $7 → $6.4
Current: $2.95
Upside: +116.95%
Recursion Pharmaceuticals
Jul 3, 2025
Assumes: Equal-Weight
Price Target: $5
Current: $5.83
Upside: -14.16%
Ascendis Pharma
May 5, 2025
Upgrades: Overweight
Price Target: $180 → $250
Current: $197.07
Upside: +26.86%
Incyte
Mar 24, 2025
Maintains: Equal-Weight
Price Target: $69 → $65
Current: $86.93
Upside: -25.23%
Axsome Therapeutics
Feb 27, 2025
Maintains: Overweight
Price Target: $125 → $190
Current: $109.42
Upside: +73.65%
Zenas BioPharma
Dec 11, 2024
Maintains: Overweight
Price Target: $40 → $35
Current: $16.85
Upside: +107.72%
Foghorn Therapeutics
Sep 24, 2024
Maintains: Equal-Weight
Price Target: $6 → $9
Current: $5.05
Upside: +78.22%
Genmab
Sep 11, 2024
Maintains: Equal-Weight
Price Target: $31
Current: $23.26
Upside: +33.28%
ABIVAX Société Anonyme
Apr 11, 2024
Maintains: Equal-Weight
Price Target: $15 → $16
Current: $70.37
Upside: -77.26%
Apr 1, 2024
Initiates: Overweight
Price Target: $30
Current: $4.34
Upside: +591.24%
Nov 13, 2023
Maintains: Overweight
Price Target: $45 → $10
Current: $16.73
Upside: -40.23%
Nov 7, 2023
Downgrades: Equal-Weight
Price Target: $46 → $6
Current: $2.90
Upside: +107.25%
Aug 29, 2023
Maintains: Overweight
Price Target: $43 → $42
Current: $8.84
Upside: +375.11%
Dec 19, 2022
Maintains: Equal-Weight
Price Target: $38 → $41
Current: $42.37
Upside: -3.23%
Dec 12, 2022
Maintains: Equal-Weight
Price Target: $120 → $40
Current: $28.06
Upside: +42.55%
Nov 10, 2022
Initiates: Equal-Weight
Price Target: $13
Current: $2.42
Upside: +437.19%
Nov 4, 2022
Maintains: Equal-Weight
Price Target: $39 → $38
Current: $19.53
Upside: +94.57%
Aug 24, 2022
Maintains: Equal-Weight
Price Target: $24 → $20
Current: $11.05
Upside: +81.00%
Jul 25, 2022
Maintains: Underweight
Price Target: $11 → $10
Current: $13.23
Upside: -24.41%
Aug 10, 2021
Initiates: Overweight
Price Target: $22
Current: $1.83
Upside: +1,105.48%
Aug 5, 2020
Maintains: Equal-Weight
Price Target: $40 → $20
Current: $9.82
Upside: +103.67%